Ratings by Credit Suisse (Evan Seigerman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/15/2023 | Ikena Oconology | IKNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/29/2022 | Ikena Oconology | IKNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Ikena Oconology | IKNA | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2021 | Ikena Oconology | IKNA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/28/2021 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2021 | Ikena Oconology | IKNA | New Coverage | Outperform (N/A) |
17.99 (1.43) |
-92.05% | Details | |
| 3/26/2021 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2021 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/5/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2021 | Satsuma Pharmaceuticals | STSA | Upgrade | Neutral (Underperform) |
5.68 (1.10) |
-80.63% | Details | |
| 2/23/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/8/2021 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2021 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/2/2021 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2021 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2021 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 12/18/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2020 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 12/16/2020 | Galera Therapeutics | GRTX | Upgrade | Outperform (Neutral) |
10.80 (0.15) |
-98.61% | Details | |
| 11/23/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2020 | Galera Therapeutics | GRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2020 | AcelRx Pharmaceuticals | ACRX | Maintain | Underperform (N/A) |
|
Details | ||
| 11/6/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2020 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2020 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/22/2020 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/21/2020 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/31/2020 | Aimmune Therapeutics | AIMT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2020 | AcelRx Pharmaceuticals | ACRX | Maintain | Underperform (N/A) |
|
Details | ||
| 8/7/2020 | Biogen | BIIB | Upgrade | Outperform (Neutral) |
277.66 (218.27) |
-21.39% | Details | |
| 8/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2020 | Aimmune Therapeutics | AIMT | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2020 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2020 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 7/20/2020 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/20/2020 | Gilead Sciences | GILD | Upgrade | Neutral (Underperform) |
77.51 (144.86) |
86.89% | Details | |
| 7/20/2020 | AcelRx Pharmaceuticals | ACRX | Downgrade | Underperform (Neutral) |
1.07 (0.86) |
-19.63% | Details | |
| 6/24/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/19/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 5/12/2020 | MacroGenics | MGNX | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/23/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2020 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2020 | Gilead Sciences | GILD | Maintain | Underperform (N/A) |
|
Details | ||
| 4/21/2020 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 4/17/2020 | Gilead Sciences | GILD | Maintain | Underperform (N/A) |
|
Details | ||
| 4/6/2020 | Gilead Sciences | GILD | Maintain | Underperform (N/A) |
|
Details | ||
| 3/24/2020 | AcelRx Pharmaceuticals | ACRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/23/2020 | AcelRx Pharmaceuticals | ACRX | Maintain | Neutral (N/A) |
|
Details | ||
| 3/11/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2020 | Aimmune Therapeutics | AIMT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/26/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2020 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/6/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/5/2020 | Gilead Sciences | GILD | Maintain | Underperform (N/A) |
|
Details | ||
| 2/4/2020 | Aimmune Therapeutics | AIMT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/23/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 1/3/2020 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2019 | Incyte | INCY | Maintain | Neutral (N/A) |
|
Details | ||
| 12/13/2019 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2019 | Gilead Sciences | GILD | Downgrade | Underperform (Neutral) |
67.78 (77.51) |
14.36% | Details | |
| 12/13/2019 | Aimmune Therapeutics | AIMT | Downgrade | Neutral (Outperform) |
30.79 (34.49) |
12.02% | Details | |
| 12/13/2019 | Neurocrine Bio. | NBIX | Downgrade | Neutral (Outperform) |
113.25 (155.30) |
37.13% | Details | |
| 12/13/2019 | Biogen | BIIB | Upgrade | Neutral (Underperform) |
292.23 (277.66) |
-4.99% | Details | |
| 12/13/2019 | Regeneron Pharma | REGN | Upgrade | Outperform (Neutral) |
373.53 (833.16) |
123.05% | Details | |
| 12/9/2019 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/11/2019 | AcelRx Pharmaceuticals | ACRX | Downgrade | Neutral (Outperform) |
1.94 (0.86) |
-55.67% | Details | |
| 11/6/2019 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2019 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Underperform (N/A) |
|
Details | ||
| 8/16/2019 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/12/2019 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/21/2019 | Regeneron Pharma | REGN | New Coverage | Neutral (N/A) |
304.94 (833.16) |
173.22% | Details | |
| 5/21/2019 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
66.36 (144.86) |
118.29% | Details | |
| 5/21/2019 | Neurocrine Bio. | NBIX | New Coverage | Outperform (N/A) |
79.03 (155.30) |
96.51% | Details | |
| 5/21/2019 | Vertex | VRTX | New Coverage | Outperform (N/A) |
168.73 (542.15) |
221.31% | Details | |
| 5/21/2019 | Incyte | INCY | New Coverage | Neutral (N/A) |
77.20 (128.59) |
66.57% | Details | |
| 5/21/2019 | Amgen | AMGN | New Coverage | Outperform (N/A) |
169.91 (433.59) |
155.19% | Details | |
| 5/21/2019 | Biogen | BIIB | New Coverage | Underperform (N/A) |
229.28 (218.27) |
-4.8% | Details | |
| 5/21/2019 | Aimmune Therapeutics | AIMT | New Coverage | Outperform (N/A) |
20.11 (34.49) |
71.51% | Details |
